0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Cyclosporine-Ketoconazole Combination Offers Promise in Reducing Antirejection Therapy Costs

Teri Randall
JAMA. 1990;264(4):430-431. doi:10.1001/jama.1990.03450040018004.
Text Size: A A A
Published online

ABSTRACT

RESEARCHERS have wed the prince of immunosuppressive drugs, cyclosporine, to a common antifungal medication, ketoconazole, and this union has been shown to slash the costs of antirejection therapy in patients who have undergone kidney transplantation by more than 80%.

Historically, Sandoz Pharmaceuticals Corporation (East Hanover, NJ), the manufacturer of cyclosporine, has discouraged the concomitant use of ketoconazole (Nizoral, Janssen Pharmaceutica Inc, Piscataway, NJ) because it creates dangerously high cyclosporine levels in the blood. But the kidney transplant team at the University of Cincinnati (Ohio) reports it has harnessed this property of ketoconazole to allow a reduction in the cyclosporine dosage by 70% in the first week and up to 88% after 18 months.

"If found to be safe and effective, this drug interaction has enormous potential for reductions in the costs associated with organ transplantation," says Roy First, MD, director of the University of Cincinnati Medical Center's kidney transplantation section.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();